Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Markella V. Zanni, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Markella Zanni and Kathleen Fitch.
Markella Zanni
Connection Strength
2.982
Kathleen Fitch
  1. Myocardial Steatosis Among Antiretroviral Therapy-Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S63-S69.
    View in: PubMed
    Score: 0.227
  2. Correlates and Timing of Reproductive Aging Transitions in a Global Cohort of Midlife Women With Human Immunodeficiency Virus: Insights From the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S20-S30.
    View in: PubMed
    Score: 0.227
  3. Successful recruitment of a multi-site international randomized placebo-controlled trial in people with HIV with attention to diversity of race and ethnicity: critical role of central coordination. HIV Res Clin Pract. 2020 02; 21(1):11-23.
    View in: PubMed
    Score: 0.222
  4. Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. . 2018 08 01; 78(4):421-428.
    View in: PubMed
    Score: 0.198
  5. Epicardial adipose tissue volume and cardiovascular risk indices among asymptomatic women with and without HIV. Antivir Ther. 2018; 23(1):1-9.
    View in: PubMed
    Score: 0.190
  6. Sex Differences in Select Non-communicable HIV-Associated Comorbidities: Exploring the Role of Systemic Immune Activation/Inflammation. Curr HIV/AIDS Rep. 2017 12; 14(6):220-228.
    View in: PubMed
    Score: 0.189
  7. Proprotein Convertase Subtilisin/Kexin 9 Levels in Relation to Systemic Immune Activation and Subclinical Coronary Plaque in HIV. Open Forum Infect Dis. 2017; 4(4):ofx227.
    View in: PubMed
    Score: 0.188
  8. Aspartame Intake Relates to Coronary Plaque Burden and Inflammatory Indices in Human Immunodeficiency Virus. Open Forum Infect Dis. 2017; 4(2):ofx083.
    View in: PubMed
    Score: 0.182
  9. Follow YOUR Heart: development of an evidence-based campaign empowering older women with HIV to participate in a large-scale cardiovascular disease prevention trial. HIV Clin Trials. 2017 03; 18(2):83-91.
    View in: PubMed
    Score: 0.180
  10. Subclinical myocyte injury, fibrosis and strain in relationship to coronary plaque in asymptomatic HIV-infected individuals. AIDS. 2016 09 10; 30(14):2205-14.
    View in: PubMed
    Score: 0.174
  11. Reduced ovarian reserve relates to monocyte activation and subclinical coronary atherosclerotic plaque in women with HIV. AIDS. 2016 Jan 28; 30(3):383-93.
    View in: PubMed
    Score: 0.167
  12. 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III cholesterol guidelines applied to HIV-infected patients with/without subclinical high-risk coronary plaque. AIDS. 2014 Sep 10; 28(14):2061-70.
    View in: PubMed
    Score: 0.151
  13. Cardiovascular Risk and Health Among People With HIV Eligible for Primary Prevention: Insights From the REPRIEVE Trial. Clin Infect Dis. 2021 Jun 16.
    View in: PubMed
    Score: 0.060
  14. Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention. JAMA Netw Open. 2021 Jun 01; 4(6):e2114923.
    View in: PubMed
    Score: 0.060
  15. Corrigendum to: Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2021 02 03; 223(2):352.
    View in: PubMed
    Score: 0.059
  16. Differential Plasma Protein Regulation and Statin Effects in Human Immunodeficiency Virus (HIV)-Infected and Non-HIV-Infected Patients Utilizing a Proteomics Approach. J Infect Dis. 2020 08 17; 222(6):929-939.
    View in: PubMed
    Score: 0.057
  17. Characteristics of REPRIEVE Trial Participants Identifying Across the Transgender Spectrum. J Infect Dis. 2020 07 09; 222(Suppl 1):S31-S40.
    View in: PubMed
    Score: 0.057
  18. Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in the REPRIEVE Trial. J Infect Dis. 2020 07 09; 222(Suppl 1):S8-S19.
    View in: PubMed
    Score: 0.057
  19. Measures of Adipose Tissue Redistribution and Atherosclerotic Coronary Plaque in HIV. Obesity (Silver Spring). 2020 04; 28(4):749-755.
    View in: PubMed
    Score: 0.055
  20. Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers. Am Heart J. 2019 06; 212:1-12.
    View in: PubMed
    Score: 0.052
  21. Rationale and design of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE). Am Heart J. 2019 06; 212:23-35.
    View in: PubMed
    Score: 0.052
  22. Relationship of visceral and subcutaneous adipose depots to markers of arterial injury and inflammation among individuals with HIV. AIDS. 2019 02 01; 33(2):229-236.
    View in: PubMed
    Score: 0.051
  23. Assessing statin effects on cardiovascular pathways in HIV using a novel proteomics approach: Analysis of data from INTREPID, a randomized controlled trial. EBioMedicine. 2018 Sep; 35:58-66.
    View in: PubMed
    Score: 0.050
  24. Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV. AIDS. 2017 03 27; 31(6):797-806.
    View in: PubMed
    Score: 0.045
  25. Increased FDG uptake in association with reduced extremity fat in HIV patients. Antivir Ther. 2013; 18(2):243-8.
    View in: PubMed
    Score: 0.033
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.